Show simple item record

A randomised evaluation of low-dose cytarabine arabinoside plus lenalidomide versus single-agent low-dose cytarabine arabinoside in older patients with acute myeloid leukaemia: results from the LI-1 Trial

dc.contributor.authorCoplan, M.
dc.contributor.authorAriti, C.
dc.contributor.authorThomas, I.
dc.contributor.authorUpton, L.
dc.contributor.authorSydenham, M.
dc.contributor.authorMehta, P.
dc.contributor.authorIslam, S.
dc.contributor.authorKjeldsen, L.
dc.contributor.authorBurnett, A. K.
dc.contributor.authorHills, R.
dc.contributor.authorRussell, N. H.
dc.contributor.authorDennis, Michael
dc.date.accessioned2022-10-19T13:13:19Z
dc.date.available2022-10-19T13:13:19Z
dc.date.issued2021en
dc.identifier.citationCoplan M, Ariti C, Thomas I, Upton L, Sydenham M, Mehta P, et al. A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial. Blood. 2021 Nov;138. PubMed PMID: WOS:000736398804290.en
dc.identifier.doi10.1182/blood-2021-147802en
dc.identifier.urihttp://hdl.handle.net/10541/625637
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1182/blood-2021-147802en
dc.titleA randomised evaluation of low-dose cytarabine arabinoside plus lenalidomide versus single-agent low-dose cytarabine arabinoside in older patients with acute myeloid leukaemia: results from the LI-1 Trialen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentPaul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgowen
dc.identifier.journalBlooden
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record